nct_id: NCT05978492
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-08-07'
study_start_date: '2023-07-27'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: TXN10128'
  - drug_name: 'Drug: Irinotecan'
  - drug_name: 'Drug: Paclitaxel'
long_title: A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study
  of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan
  or Paclitaxel in Locally Advanced or Metastatic Solid Tumors
last_updated: '2025-04-24'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: Min-Hee Ryu, M.D., Ph.D.
principal_investigator_institution: Asan Medical Center
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 96
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- "* Male or female subjects \u226519 years of age at the time of informed consent."
- '* Histologically and/or cytologically confirmed any progressive, locally advanced
  (unresectable), or metastatic solid tumors that have relapsed or are refractory
  following the last line of treatment and for which prior standard therapy has been
  ineffective, or standard therapy does not exist or is not considered appropriate.'
- '* ECOG performance status of 0 or 1.'
- '* Life expectancy of at least 12 weeks.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Has leptomeningeal disease.
- "Exclude - * Experienced a Grade \u22653 immune-related adverse events (irAE) with\
  \ prior immunotherapy with the exception of non-clinically significant laboratory\
  \ abnormalities."
- Exclude - * Prior organ transplantation.
- Exclude - * Known positive human immunodeficiency virus (HIV) infection.
short_title: A Study of TXN10128 in Subjects With Solid Tumors
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Txinno Bioscience Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: 'This is a phase I clinical trial to primarily evaluate the safety, tolerability,
  and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity
  of investigational product, TXN10128. The target subjects will be consisted of patients
  with locally advanced (unresectable) or metastatic soild tumors.


  This study includes a dose-escalation part and a dose-expansion part, and a TXN10128
  monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.'
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Cohort A-1
      arm_internal_id: 0
      arm_description: TXN10128 Monotherapy Dose esclation part
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TXN10128'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Cohort B-1
      arm_internal_id: 1
      arm_description: Combination Therapy with TXN10128 and Irinotecan Dose esclation
        part
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TXN10128'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Irinotecan'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Cohort C-1
      arm_internal_id: 2
      arm_description: Combination therapy with TXN10128 and Paclitaxel Dose esclation
        part
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: TXN10128'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Paclitaxel'
        level_internal_id: 1
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=19'
        disease_status:
        - Locally Advanced
        - Unresectable
        - Metastatic
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: _SOLID_
